# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ernest Shackleton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX001-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cormac Ellingsworth-Daly, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Ten-week review, three weeks after a coronary stent. **S**

## History of present illness

Mr. Shackleton returns three weeks after coronary angiography, at which a drug-eluting stent was placed in the proximal left anterior descending artery through the right wrist, with no complications; he went home the same day. He has had no chest tightness since, even on the stairs with a load, and has not needed nitroglycerin. The wrist bruise has faded. He takes aspirin and clopidogrel every day and has had no bleeding beyond easy bruising on his forearms. He has not smoked for nine weeks. He drinks on four or five evenings a week, usually two drinks, sometimes three at dinners. He is impatient to get fit for the voyage. **S**

| Element | Detail |
|---|---|
| Angina | None since the stent |
| Access site | Right wrist healed |
| Antiplatelets | Aspirin and clopidogrel daily; minor bruising only |
| Tobacco | Not smoked for nine weeks |
| Alcohol | Two, sometimes three, drinks on four or five evenings a week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, or swelling |
| Hematologic | Positive | Easy bruising on the forearms; no nosebleeds, black stools, or blood in the urine |
| Musculoskeletal | Negative | No muscle aches |

3 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeat every 5 minutes up to 3 doses **S**
- Varenicline 1 mg tablet, one tablet by mouth twice a day after a one-week starter titration **S**
- Metoprolol succinate extended-release 100 mg tablet, one tablet by mouth daily **S**
- Clopidogrel 75 mg tablet, one tablet by mouth daily for six months after the stent (600 mg loading dose before the procedure) **S**
- Ezetimibe 10 mg tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/78 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 84.4 kg; BMI 27.6 kg/m². All vital signs are synthetic.

Total cholesterol: 128 mg/dL; HDL cholesterol: 44 mg/dL; LDL cholesterol: 62 mg/dL; Triglycerides: 110 mg/dL; ALT: 31 U/L; AUDIT-C: 4. All results are synthetic.

## Change since baseline

- Total cholesterol: 246 mg/dL (high) at baseline, 128 mg/dL at this visit **S**
- HDL cholesterol: 38 mg/dL (low) at baseline, 44 mg/dL at this visit **S**
- LDL cholesterol: 168 mg/dL (high) at baseline, 62 mg/dL at this visit **S**
- Triglycerides: 200 mg/dL (high) at baseline, 110 mg/dL at this visit **S**
- ALT: 41 U/L at baseline, 31 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 124/78, pulse 58, weight 84.4 kg |
| Cardiovascular | Regular rhythm; no murmur; right radial pulse normal; access site healed |
| Skin | Two small bruises on the forearms |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Drug-eluting stent in the proximal LAD, on dual antiplatelet therapy** (Z95.5). Free of angina since the stent. Minor bruising only. **S**
   - Aspirin with clopidogrel for six months from the stent, then aspirin alone; never stop clopidogrel early without asking cardiology.
   - No NSAIDs.
2. **Chronic coronary disease** (I25.118). LDL cholesterol 62 mg/dL after ten weeks of atorvastatin 80 mg, down 63% from 168 but above the target below 55 mg/dL; total cholesterol 128, HDL 44, triglycerides 110 mg/dL; ALT 31 U/L. Blood pressure at target. **S**
   - Add ezetimibe 10 mg daily.
   - Lipid panel in about seven weeks, at the pre-departure visit.
   - Cardiac rehabilitation three times a week from next week.
3. **Nicotine dependence, cigarettes** (F17.210). Abstinent for nine weeks. **S**
   - Continue varenicline to 24 weeks.
4. **Drinking above the low-risk limit at times**. AUDIT-C 4, at the threshold for men, down from an AUDIT of 12. Brief intervention repeated: no more than two drinks a day, with alcohol-free days, and less at sea. **S**
   - AUDIT-C at the pre-departure visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 124/78 mmHg, at target |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 84.4 kg; walking daily |
| Examination | Angina frequency and Canadian Cardiovascular Society class, nitroglycerin use | Every visit | Completed today | No angina since the stent; no nitroglycerin |
| Medication safety | Dual antiplatelet therapy: adherence and bleeding | Every visit during dual therapy | Completed today | Both taken daily; minor bruising only; no NSAIDs |
| Medication safety | Adherence review: aspirin (or dual antiplatelet therapy), high-intensity statin, beta-blocker for angina | Every visit | Completed today | Atorvastatin, metoprolol, and both antiplatelets taken daily |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months | Completed today | LDL 62 mg/dL (63% reduction), above the target below 55; ezetimibe added |
| Laboratory | ALT on high-intensity statin | Baseline, then only with symptoms | Completed today | 31 U/L; drawn with the lipid panel |
| Imaging | Stress imaging, coronary CT angiography, echocardiography, or invasive angiography | Only for new or worsening symptoms or a change in function despite optimized therapy; no routine surveillance | Not indicated | Asymptomatic after the stent; no surveillance imaging |
| Self-management | Tobacco use and cessation support (varenicline with counseling) | Every visit | Completed today | Abstinent for nine weeks |
| Survey | Alcohol use (AUDIT-C) and brief intervention | Each visit until within limits | Completed today | AUDIT-C 4, at the threshold; brief intervention repeated |
| Referral | Cardiac rehabilitation referral | At diagnosis of stable angina, and after PCI | Referred | Referred today; first session next week. Protocol deviation: the referral was due at the diagnosis of stable angina at the consultation and was deferred for eight weeks while revascularization was decided. No harm is evident: he had no cardiac events and is angina-free. Corrective action: refer at diagnosis in future, whatever revascularization plan is pending |
| Laboratory | HbA1c for prediabetes | Every 3 to 6 months while lifestyle change is under way, then yearly | Due | At the pre-departure visit |

## Goal progress

- No cigarettes from the quit date, confirmed at each visit. In progress; target 2026-09-08. **S**
- LDL cholesterol below 55 mg/dL with at least a 50% reduction by four months. In progress; target 2026-09-08. **S**
- Blood pressure below 130/80 mmHg by six weeks. Outcome by 2026-06-23: 128/80 at six weeks. **S**
- Free of angina in daily activity, and a symptom-limited exercise test of at least 10 METs without ischemia before departure. In progress; target 2026-09-08. **S**
- Drinking within the low-risk limit, with an AUDIT-C below 4, by four months. In progress; target 2026-09-08. **S**
- At least 15 sessions of cardiac rehabilitation before departure. In progress; target 2026-09-08. **S**

## Medication changes

- Started: Ezetimibe 10 mg tablet, one tablet by mouth daily **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Virani SS, et al. Circulation 2023;148(9):e9-e119) (2023), American Heart Association and American College of Cardiology
- 2024 ESC Guidelines for the management of chronic coronary syndromes (Vrints C, et al. Eur Heart J 2024;45(36):3415-3537) (2024), European Society of Cardiology
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit in three weeks. Pre-departure review in seven weeks with an exercise test, lipids, and HbA1c. **S**
- Next scheduled visit 2026-08-11: periodic adult preventive visit. **S**
